Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-8080 Monotherapy and Combination in Advanced Breast Cancer
NCT05189717Phase 1Unknown
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
- Start
- Feb 2022
- Primary completion
- Oct 2024
- Modality
- Molecular Glues
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HRS-8080 in breast cancer, sponsored by Shandong Suncadia Medicine Co., Ltd. Primary endpoints: Maximum tolerated dose up to 28 days, Recommended phase II dose up to 28 days and 1 more. Status: unknown.
02
Drugs
HRS-8080
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05189717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05189717.